Fostamatinib
CAS 901119-35-5
Fostamatinib (CAS 901119-35-5) is a pharmaceutical compound with 80 bioactivity targets and 443 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Death-associated protein kinase 2 Kinase |
Kd | 7.21 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 7.44 | - | Homo sapiens |
| Macrophage-stimulating protein receptor Kinase |
Kd | 6.33 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 7.3 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 8.48 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 6.77 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 8.6 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 7.21 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 8.08 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 7.52 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 7.46 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 7.55 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 6.85 | - | Homo sapiens |
| RAF proto-oncogene serine/threonine-protein kinase Kinase |
Kd | 6.08 | - | Homo sapiens |
| Serine/threonine-protein kinase B-raf Kinase |
Kd | 6.62 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 9.43 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
IC50 | 8.3 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 1 Kinase |
Kd | 7.8 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 2 Kinase |
Kd | 7.16 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 3 Kinase |
Kd | 8.04 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 7.51 | - | Homo sapiens |
| Platelet-derived growth factor receptor alpha Kinase |
Kd | 7.22 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 5.1 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 6.03 | - | Homo sapiens |
| Insulin-like growth factor 1 receptor Kinase |
Kd | 5.89 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 5.19 | - | Homo sapiens |
| Insulin receptor Kinase |
Kd | 5.96 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 7.89 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 6.64 | - | Homo sapiens |
| Mitogen-activated protein kinase 8 Kinase |
EC50 | 8 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 7.25 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 6.23 | - | Homo sapiens |
| Focal adhesion kinase 1 Kinase |
Kd | 6.6 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 6.82 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Kd | 7.68 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK1 Kinase |
Kd | 6.08 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-4 Kinase |
Kd | 6.22 | - | Homo sapiens |
| Mitogen-activated protein kinase 10 Kinase |
Kd | 7.43 | - | Homo sapiens |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase |
Kd | 5.38 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 6.77 | - | Homo sapiens |
| Protein kinase C delta type Kinase |
Kd | 5.39 | - | Homo sapiens |
| cAMP-dependent protein kinase catalytic subunit beta Kinase |
Kd | 6.29 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 8.46 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 6.25 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase |
Kd | 5.52 | - | Homo sapiens |
| Tyrosine-protein kinase CSK Kinase |
Kd | 6.8 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 6.51 | - | Homo sapiens |
| Ephrin type-A receptor 8 Kinase |
Kd | 5.89 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 6.04 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 6.39 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Platelet count decreased | 74 | 190.268 | 10035528 |
| Platelet count | 14 | 121.854 | 10035525 |
| Diarrhoea | 75 | 84.803 | 10012735 |
| Death | 58 | 68.508 | 10011906 |
| Hospitalisation | 29 | 61.494 | 10054112 |
| Drug ineffective | 65 | 47.287 | 10013709 |
| Off label use | 57 | 46.06 | 10053762 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| FOSTAMATINIB | 2044896 | SU | MTHSPL |
| fostamatinib | 2044896 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Fostamatinib used for in pharmaceutical contexts?
Fostamatinib (CAS 901119-35-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Fostamatinib?
Fostamatinib has 443 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Platelet count decreased, Platelet count, Diarrhoea, Death, Hospitalisation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Fostamatinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Fostamatinib.
What clinical phase is Fostamatinib in?
No phase 1-4 clinical development badge is rendered for Fostamatinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Fostamatinib?
Fostamatinib has 264 bioactivity rows in this page query. Rendered target entries include Death-associated protein kinase 2, Tyrosine-protein kinase JAK3, Macrophage-stimulating protein receptor, ATP-binding cassette sub-family G member 2, Platelet-derived growth factor receptor beta.